ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Eli Lilly and Samsung Bioepis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Eli LillySamsung Bioepis
studies on the registry2,26233
open to participants now1732
phase 3 studies under way1041
reach primary completion within a year1041
programswith a study of their own in two years93+3 named only4

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseEli LillySamsung Bioepis
Phase 1

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%

Samsung Bioepis: 2 of its 4 programs at phase 1

  1. ixekizumabphase 1
  2. potassium L-ascorbatephase 1
50%
Phase 2

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%

Samsung Bioepis: 2 of its 4 programs at phase 2

  1. Ranibizumabphase 2
  2. afliberceptphase 2
50%
Phase 3

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%
00%
Approved, new studies

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
Samsung Bioepis1 readouts · 0 phase 3·······

Samsung Bioepis, Jun ’27: 1 program whose next study reaches primary completion

  1. ixekizumabphase 1 · Jun 9 · NCT07789964
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Eli Lilly

New programs 8

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Samsung Bioepis

New programs 1

  • afliberceptphase 2 · first study · Sep 21 · Macular Degeneration

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionEli LillySamsung Bioepis
Psoriasisboth · compare here

Eli Lilly in Psoriasis: 5 programs

  1. eltrekibartphase 2
  2. simepdekinraphase 2
  3. DC-806phase 2
  4. Tirzepatideapproved, new study
  5. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Psoriasis in search

Samsung Bioepis in Psoriasis: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Psoriasis in search

Arthritis, Rheumatoidboth · compare here

Eli Lilly in Arthritis, Rheumatoid: 4 programs

  1. clazakizumabphase 2
  2. sevoloprubartphase 2
  3. LY4213663phase 1
  4. baricitinibapproved, new study

Their studies: Eli Lilly’s studies of Arthritis, Rheumatoid in search

Samsung Bioepis in Arthritis, Rheumatoid: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Arthritis, Rheumatoid in search

Arthritis, Psoriaticboth · compare here

Eli Lilly in Arthritis, Psoriatic: 1 program

  1. clazakizumabphase 2

Their studies: Eli Lilly’s studies of Arthritis, Psoriatic in search

Samsung Bioepis in Arthritis, Psoriatic: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Arthritis, Psoriatic in search

Colorectal Neoplasmsboth · compare here

Eli Lilly in Colorectal Neoplasms: 1 program

  1. olomorasibphase 3

Their studies: Eli Lilly’s studies of Colorectal Neoplasms in search

Samsung Bioepis in Colorectal Neoplasms: 1 program

  1. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Colorectal Neoplasms in search

Lymphoma, Non-Hodgkinboth · compare here

Samsung Bioepis in Lymphoma, Non-Hodgkin: 1 program

  1. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Lymphoma, Non-Hodgkin in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetEli LillySamsung Bioepis
IL17Asimepdekinraixekizumabrule
A target, or a pathogen for a vaccine, known for: Eli Lilly 50 of 93 · Samsung Bioepis 3 of 4 programs (25 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3).